

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
04 October 2018 (04.10.2018)



(10) International Publication Number
WO 2018/178396 A1

(51) International Patent Classification:
C07K 16/28 (2006.01) **A61P 35/00** (2006.01)

(21) International Application Number:
PCT/EP2018/058479

(22) International Filing Date:
03 April 2018 (03.04.2018)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/479,712 31 March 2017 (31.03.2017) US
PCT/EP2018/057836
27 March 2018 (27.03.2018) EP

(71) Applicant: **GENMAB HOLDING B.V.** [NL/NL]; Uppsalalaan 15, 3584 CT Utrecht (NL).

(72) Inventors: **OOSTINDIE, Simone**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **BEURSKENS, Frank**; c/o GENMAB B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **BREIJ, Esther**; c/o Gebmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **VAN DEN BRINK, Edward**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **HOLLENSTEIN, Andreas**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **OVERDIJK, Marije**; c/o Genmab B.V. Uppsalalaan 15, 3584 CT Utrecht (NL). **LINDORFER, Margaret**; 276 Spring Meadow Lane, Keswick, Virginia 22947 (US). **TAYLOR, Ronald**; 276 Spring Meadow Lane, Keswick, Virginia 22947 (US). **PARREN, Paul**; Werdorperwaard 17, 3984 PR Odijk (NL). **VAN DER HORST, Hilma**; Schoolstraat 1bis, 3581 PM Utrecht (NL). **E.D. CHAMULEAU, Martine**; VU University Medical Center Department of Hematology De Boelelaan 1117, 1081 HV Amsterdam (NL). **MUTIS, Tuna**; VU University Medical Center De Boelelaan 1117, Building CCA, 4.022, 1081 HV Amsterdam (NL).

(74) Agent: **GENMAB A/S**; Kalvebod Brygge 43, DK-1560 Copenhagen V (DK).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,

SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: BISPECIFIC ANTI-CD37 ANTIBODIES, MONOCLONAL ANTI-CD37 ANTIBODIES AND METHODS OF USE THEREOF

(57) Abstract: CD37-specific bispecific antibody molecules binding to different epitopes of the human CD37 antigen which bispecific antibody molecules have enhanced Fc-Fc interactions upon binding to CD37 on the cell surface. The invention also relates to the monoclonal parental antibodies from which the first or the second binding region of the bispecific antibody molecules is obtained. The invention also relates to pharmaceutical compositions containing these molecules and the treatment of cancer and other diseases using these compositions.

WO 2018/178396 A1